PEG-MGF
A PEGylated version of MGF with extended half-life for systemic muscle growth and recovery effects.
What is PEG-MGF?
PEG-MGF is a PEGylated form of Mechano Growth Factor where a polyethylene glycol molecule is attached to increase stability and extend the half-life from minutes to several hours. This allows systemic distribution and longer-lasting effects compared to standard MGF, though it may sacrifice some of the localized potency.
What PEG-MGF Is Investigated For
PEG-MGF is a PEGylated synthetic form of the mechano growth factor E-domain peptide, marketed in bodybuilding and recovery contexts for systemic muscle growth, satellite-cell activation, and anti-inflammatory and tissue-protective effects in muscle injury. The underlying biology — endogenous MGF expression in mechanically loaded muscle, satellite-cell proliferation, macrophage modulation, and animal injection studies showing benefit in injury models — is moderately supported by Goldspink's original work and follow-up animal studies. But PEG-MGF itself has no published human clinical trial of any kind: no human pharmacokinetic data, no efficacy trial in any population, and a 2013 study (Fornaro et al.) reporting that the isolated E-peptide had no apparent effect on myoblasts or muscle stem cells in isolation, directly contradicting the mechanistic premise behind commercial use. Anti-PEG antibody concerns with repeated exposure and the explicit WADA S2 prohibition for athletes add further caveats. The honest framing: animal-model rationale and extrapolation, no human trial data for the pegylated synthetic product, and detection methods now exist for anti-doping controls.
History & Discovery
PEG-MGF is the pegylated synthetic form of Mechano Growth Factor, a locally acting splice variant of insulin-like growth factor 1 (IGF-1Ec) identified in the early 1990s by Geoffrey Goldspink and colleagues at the Royal Free Hospital in London. Goldspink's group was investigating why skeletal muscle responds to mechanical loading and found that mechanical stress triggered alternative splicing of the IGF-1 gene, producing a transcript with a distinctive C-terminal extension — the 'E-domain' — that differed from the systemically circulating liver-derived IGF-1. This splice variant was shown to be released locally in damaged and mechanically loaded muscle, where it appeared to activate satellite (muscle stem) cells and promote the early proliferative phase of muscle repair before the tissue transitions to differentiation. Goldspink coined the 'mechano growth factor' name to reflect this mechanical-load-dependent expression. Native MGF has a very short functional half-life — minutes to low single-digit hours — because the E-domain peptide is rapidly cleared and degraded, which is consistent with its biological role as a local paracrine signal rather than a circulating hormone. PEG-MGF was developed as a research-chemical product by attaching a polyethylene glycol polymer to the synthetic E-domain peptide, a standard pharmaceutical stabilization approach that extends half-life by reducing renal clearance and proteolytic degradation. This migration into the research-chemical and bodybuilding market occurred in the 2000s, well before any controlled human study of the synthetic form. Critically, PEG-MGF has never been developed through a regulated pharmaceutical pathway: there is no FDA-registered PEG-MGF product, no published Phase I human pharmacokinetic data for the pegylated synthetic form, and no controlled efficacy trial in any human population. Most of the biological rationale cited for its use is extrapolated from Goldspink's original work on native MGF expression in exercised muscle and from animal models of injected MGF in injury contexts.
How It Works
PEG-MGF is a longer-lasting version of the muscle repair signal MGF. The PEG coating protects it from breakdown, allowing it to circulate throughout the body and support muscle recovery systemically rather than just locally.
MGF (IGF-1Ec) is a splice variant of IGF-1 produced in response to mechanical stress. Its unique C-terminal E-domain peptide activates muscle satellite (stem) cells independently of the IGF-1 receptor, promoting proliferation before differentiation. PEGylation of this E-domain peptide reduces renal clearance and protease degradation, extending systemic half-life from minutes to hours. Research shows MGF modulates inflammatory cytokine expression and macrophage polarization during muscle injury, promotes angiogenesis, and has demonstrated cardioprotective effects by inhibiting apoptosis after myocardial infarction. The E-domain also shows neuroprotective activity in ischemia models. Full-length MGF activates the IGF-1R with potency similar to recombinant IGF-1 at equimolar concentrations, while the isolated E-peptide appears to act through distinct, not fully characterized signaling pathways including ERK1/2 and Akt.
Evidence Snapshot
Human Clinical Evidence
No clinical trials of PEG-MGF itself. Human studies are limited to endogenous MGF expression measured after resistance exercise, confirming MGF mRNA upregulation in muscle biopsies. One study of PEGylated recombinant IGF-1 (not MGF specifically) showed extended half-life in humans.
Animal / Preclinical
Moderate for native MGF. Animal studies demonstrate MGF injection ameliorates impaired muscle regeneration, reduces cardiac damage post-infarction, provides neuroprotection in ALS models, and modulates inflammatory responses. PEG-MGF-specific animal data remain limited.
Mechanistic Rationale
Strong. MGF E-domain activates satellite cells, inhibits apoptosis, modulates macrophage polarization, and promotes angiogenesis through ERK1/2, Akt, and RhoA-YAP pathways. PEGylation pharmacokinetics are well-established.
Research Gaps & Open Questions
What the current literature has not yet settled about PEG-MGF:
- 01Basic human pharmacokinetics — no published study has characterized absorption, distribution, or clearance of synthetic PEG-MGF in humans at any dose.
- 02Efficacy in any human endpoint — no controlled trial has tested PEG-MGF for muscle growth, recovery, injury repair, or any other endpoint in humans. All efficacy claims rest on extrapolation from native-MGF animal models or from MGF expression studies in exercised human muscle.
- 03Whether the isolated E-domain peptide actually produces the satellite-cell activation effects attributed to it — a 2013 study (Fornaro and colleagues) reported that the isolated E-peptide had no apparent effect on myoblasts or primary muscle stem cells, contradicting earlier findings and raising real questions about the fragment's biological activity in isolation.
- 04Long-term safety of PEG exposure — anti-PEG antibody formation and accelerated blood clearance phenomena are documented concerns for pegylated biologics; whether these arise with PEG-MGF specifically has not been characterized.
- 05Tumor biology interactions — the theoretical cancer-relevant signaling overlap (satellite-cell proliferation, angiogenic modulation, IGF-family activity) has not been quantified in long-duration carcinogenicity or pharmacovigilance data.
- 06Comparative characterization against native MGF, full-length IGF-1Ec, IGF-1 LR3, and IGF-1 DES for any defined biological endpoint in a controlled setting.
Forms & Administration
SC or IM injection. Typical research dose: 200mcg, 2-3 times per week. Can be injected systemically rather than site-specifically. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
There is no published human dose-ranging data for PEG-MGF specifically; the commonly cited doses are entirely drawn from research-chemical and bodybuilding-community practice rather than clinical studies. The most frequently referenced range is 100–500 mcg per injection, with 200 mcg per dose being a typical mid-range number in circulated protocols. These doses are extrapolated partly from native MGF animal studies scaled by body weight and partly from analogous dosing of other IGF-1-family peptides; they should not be read as validated.
Frequency
Circulated protocols typically describe 2–3 injections per week, a cadence justified by PEG-MGF's theoretical multi-hour half-life compared to native MGF's minutes-to-hours duration. Post-workout dosing is commonly recommended on the rationale that mechanical muscle damage creates the biological context in which MGF signaling is naturally active, though this rationale rests on native MGF biology rather than on any study of synthetic PEG-MGF timing. Daily dosing is not typical; it would likely saturate receptor signaling without pharmacodynamic benefit given the pegylated pharmacokinetics.
Timing Considerations
Time of day
Less tightly tied to individual training sessions than standard MGF because pegylation extends half-life into the multi-hour range.
Relative to meals
Commonly paired with a post-workout meal when timed around training, but the wider dosing window makes meal timing less critical than with standard MGF.
Relative to exercise
Post-workout injection is the standard pattern, typically 1–2 times weekly on training days or the day after. Unlike standard MGF, PEG-MGF does not require injection within minutes of training because its circulating half-life covers the post-exercise repair window.
Cycle Length
Commonly discussed cycles run 4–6 weeks on followed by an equivalent break. There is no evidence-based rationale for any specific cycle length — the convention is a generic research-chemical precaution rather than a validated practice. No long-duration human data exists to inform continuous vs. cycled use, long-term receptor effects, or any downstream consequences of sustained E-domain peptide exposure.
Protocol Notes
PEG-MGF is supplied as a lyophilized powder, typically 2 mg per vial, and is reconstituted in bacteriostatic water. A 2 mg vial in 1 mL yields 2,000 mcg/mL, making 200 mcg roughly 0.1 mL or 10 units on an insulin syringe. Both subcutaneous and intramuscular injection are described in circulated protocols — IM delivery into the target muscle group is favored by users pursuing a 'local' muscle-growth rationale even though the pegylated form was specifically designed to produce systemic distribution rather than local action. Post-workout timing (within 30–60 minutes) is the most common convention. All of the above is practitioner convention rather than validated dosing. PEG-MGF has no pharmacokinetic characterization in humans, no dose-response curve, and no clinical trial framework to anchor injection timing, frequency, or cycle length. Users should not mistake specificity of numbers for specificity of evidence.
PEG-MGF is not FDA-approved for any indication and has not been tested in controlled human clinical trials. The numbers above reflect research-chemical community practice, not a prescription or a validated protocol. Human safety, efficacy, and pharmacokinetic data are absent.
Timeline of Effects
Onset
User-reported onset of subjective effects — improved workout recovery, reduced post-exercise soreness — is typically described within 1–2 weeks of starting a protocol. These reports are anecdotal and unvalidated by controlled data. No human pharmacokinetic study has characterized actual serum exposure from an injection of synthetic PEG-MGF.
Peak Effect
Anecdotal reports describe peak subjective benefit emerging over 3–6 weeks of consistent dosing. There is no validated human peak-effect timeline; native MGF expression in muscle biopsies peaks within hours to days of a mechanical stimulus, but the dynamics of a pegylated exogenous E-domain peptide are not directly comparable.
After Discontinuation
The pegylated form has an extended half-life relative to native MGF, but published human clearance data does not exist. Theoretically, circulating PEG-MGF would clear over days following discontinuation, with any muscle-biology effects tied to the satellite-cell activation window rather than continued receptor occupancy. No rebound effect has been systematically described, and no suppression of endogenous systems would be expected because the E-domain peptide does not replicate a circulating regulatory hormone.
Common Questions
Who PEG-MGF Is NOT For
- •Active or recent-history cancer — MGF is a local growth factor that activates satellite cells and modulates macrophage and angiogenic signaling in ways that overlap with tumor-relevant biology. Even more than for GH secretagogues, the combination of proliferative satellite-cell signaling and angiogenic modulation makes use in active malignancy inappropriate; the absence of human oncology data means this is a precautionary rather than evidence-based contraindication, but it is the appropriate default.
- •Pregnancy — no human pregnancy safety data exists for PEG-MGF or native MGF. The E-domain peptide's role in development and its theoretical effects on fetal growth have not been characterized in reproductive-toxicology studies.
- •Breastfeeding — no data on transfer into breast milk or effects on nursing infants.
- •Pediatric use — development-related signaling effects from exogenous IGF-1 splice variants are not characterized, and pediatric use falls entirely outside any evidence base.
- •Known hypersensitivity to peptide therapeutics, pegylated compounds, or excipients in compounded preparations — immune reactions against pegylated products have been documented across multiple PEG-conjugated drug classes.
- •Uncontrolled diabetes or insulin-resistant states — IGF-1-family signaling has metabolic effects that have not been characterized for the pegylated E-domain specifically, and patients with metabolic disease carry additional unknowns.
Drug & Supplement Interactions
Documented clinical drug interactions for PEG-MGF are essentially nonexistent because human pharmacology studies are essentially nonexistent. What follows is theoretical and derived from mechanistic overlap with the IGF-1 family. The most relevant theoretical concern is with IGF-1R-modulating therapies used in oncology: pharmacologic IGF-1R activation by an E-domain fragment, whether direct or indirect, would be expected to oppose the intent of IGF-1R-targeted cancer therapies and to interact with general chemotherapy regimens that depend on intact apoptotic signaling in rapidly dividing cells. Co-administration with anti-angiogenic agents (bevacizumab, VEGF pathway inhibitors) raises concerns because MGF-family signaling includes angiogenic components in preclinical work. Glucose-regulating medications — insulin, sulfonylureas, GLP-1 receptor agonists — warrant attention because IGF-1-family activity influences insulin sensitivity and glucose disposal. The magnitude of any metabolic interaction from PEG-MGF at research-chemical doses is unquantified. Pegylated product concerns include the possibility of anti-PEG antibody formation on repeated exposure, which has been documented with other pegylated pharmaceuticals; this is a class-level concern rather than a PEG-MGF-specific finding. Patients on any regular medication should understand that absence of documented interaction does not equal absence of interaction — it equals absence of data.
Safety Profile
Common Side Effects
Cautions
- • Not FDA-approved
- • Very limited human data
- • PEGylation may alter receptor-binding potency while extending duration
- • Long-term effects unknown
- • Listed as prohibited substance by WADA
What We Don't Know
Human safety and efficacy data are essentially nonexistent for PEG-MGF specifically. One study found MGF E-peptide alone had no apparent effect on myoblasts in isolation, raising questions about the mechanism. PEGylation effects on MGF bioactivity and receptor interactions need further characterization.
Legal Status
United States
PEG-MGF is not FDA-approved for any medical indication and has not been the subject of an IND or any completed clinical trial. It is not available through any regulated therapeutic channel. It is sold in the research-chemical market labeled 'not for human consumption,' which is not an authorized channel for human use. Some compounding pharmacies have stocked it historically, though the FDA's ongoing review of peptides eligible for 503A compounding has tightened this channel for peptides lacking pharmacopoeial monographs and safety data — a category in which PEG-MGF sits.
International
No major regulator has authorized PEG-MGF as a medicine. The European Medicines Agency, UK MHRA, Health Canada, and Australia's TGA treat it as an unapproved investigational agent. Australia's TGA classifies IGF-1 splice variants and GH-family factors as Schedule 4 substances and has pursued enforcement against unapproved sales.
Sports & Competition
MGF and its synthetic analogs, including PEG-MGF, are explicitly prohibited under WADA's S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics). The WADA Prohibited List names mechano growth factors and IGF-1 analogs by category. Prohibited at all times, both in and out of competition. Mass spectrometry detection methods for synthetic full-length MGF have been published for anti-doping applications. Athletes subject to WADA, USADA, UKAD, or equivalent bodies must avoid it.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
PEG-MGF is a muscle-building peptide with established efficacy in humans.
Reality
PEG-MGF has no completed human clinical trial of any kind. The muscle-growth narrative is built from Goldspink's expression work on endogenous MGF in exercised muscle, from animal injection studies of native MGF, and from extrapolation — not from controlled data on the pegylated synthetic product. Treating PEG-MGF as a validated muscle-building agent substantially overstates what the evidence supports.
Myth
PEG-MGF works better than native MGF because the pegylation extends its action.
Reality
PEGylation unambiguously extends plasma half-life — that is what it is designed to do. But MGF's biological role is as a local, acutely expressed signal in damaged muscle, not as a circulating systemic hormone. Extending the peptide's systemic lifetime may actually move it further away from its native biological context, not closer. 'Longer-lasting' is not axiomatically 'better' for a locally acting signaling peptide.
Myth
The E-domain peptide alone reliably activates satellite cells — that is established biology.
Reality
A published study (Fornaro and colleagues, 2014) reported that the isolated MGF E-peptide had no apparent effect on myoblasts or primary muscle stem cells, directly contradicting earlier findings that had motivated the commercial interest. The current mechanistic picture is contested rather than settled, and any strong claim about E-peptide-driven satellite-cell activation should be read against that uncertainty.
Myth
PEG-MGF is FDA-approved or was in clinical trials.
Reality
PEG-MGF has never been FDA-approved and has never been the subject of a completed clinical trial published in the peer-reviewed literature. A single study of a pegylated recombinant full-length IGF-1 (not the MGF E-domain) exists, but that compound is pharmacologically distinct from PEG-MGF.
Myth
PEG-MGF is undetectable in drug testing because the peptide clears quickly.
Reality
Mass spectrometry methods for detecting synthetic MGF relevant to doping controls have been published in the anti-doping literature. MGF-family compounds are explicitly prohibited under WADA S2, and detection capability exists. Assumptions of undetectability are not supported by the current analytical landscape.
Published Research
16 studiesThe role of mechano growth factor in chondrocytes and cartilage defects: a concise review.
Impaired Skeletal Muscle Regeneration Induced by Macrophage Depletion Could Be Partly Ameliorated by MGF Injection.
Overexpression of Mechano-Growth Factor Modulates Inflammatory Cytokine Expression and Macrophage Resolution in Skeletal Muscle Injury.
First-in-man study with a novel PEGylated recombinant human insulin-like growth factor-I.
Effects of resistance training on expression of IGF-I splice variants in younger and older men.
Potency of Full-Length MGF to Induce Maximal Activation of the IGF-I R Is Similar to Recombinant Human IGF-I at High Equimolar Concentrations.
Localized delivery of mechano-growth factor E-domain peptide via polymeric microstructures improves cardiac function following myocardial infarction.
Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls.
Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells.
Mechano-Growth Factor: an important cog or a loose screw in the repair machinery?
Age-related loss of muscle mass and strength.
Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages.
Mechano-growth factor, an IGF-I splice variant, rescues motoneurons and improves muscle function in SOD1(G93A) mice.
Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction.
Impairment of IGF-I gene splicing and MGF expression associated with muscle wasting.
A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia.
Quick Facts
- Class
- PEGylated Growth Factor
- Tier
- D
- Evidence
- Preliminary
- Safety
- Limited Data
- Updated
- Mar 2026
- Citations
- 16PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.